Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA-producing cancer would be a good therapeutic target because it is found in lung, stomach and colon sites, which account for most cancers.
|
11745423 |
2001 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA RT-PCR is useful as a prognostic marker for increased risk of cancer death and peritoneal carcinomatosis, and might be useful in the clinical setting for selecting patients for various adjuvant treatments.
|
16427547 |
2006 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA inhibits circulating cancer cell death.
|
28588612 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CEA mRNA expression in the non-carcinomatous parenchymal tissue and cancer tissue was evaluated by in situ hybridisation using CEA specific riboprobe and was semiquantitated by counting the number of silver grains per cell.
|
7638808 |
1995 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA has been involved in vitro in adhesion mechanisms, but little is known about the function of this glycoprotein in vivo in normal tissue differentiation and malignancy.
|
8813148 |
1996 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among normal group, hyperplasia group and cancer group, the CEA expression levels were 2.26 ng/ml, 3.85 ng/ml and 16.08 ng/ml, respectively.
|
29050322 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a conclusion, CEA and EpCAM are invariably expressed by pseudomyxoma peritonei tumor cells and could be exploited to targeted therapies against this malignancy.
|
27038681 |
2016 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
At current work, the combination of sensors were used to detect the presence of BCR-ABL1 as a mutant gene and CEA as a biomarkers of cancer, such a capability makes the package liable for early and certain detection of acute lymphoblastic leukemia.
|
31295447 |
2019 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01).
|
17177160 |
2007 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Beyond simple size and cystic fluid CEA determination, microRNA (miRNA) detection holds great promise as molecular diagnostics for cancer risk.
|
23884752 |
2013 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
First, the serum level of CEA in GC patients with a cardia-located cancer was significantly higher than in patients with pyloric antrum-located cancer (p=0.050).
|
23787496 |
2013 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence resonance energy transfer (FRET) between fluorescein isothiocyanate (FITC) and gold nanoparticles (Au NPs) is introduced in the lateral flow strip to detect cancer biomarker CEA with the color and fluorescence dual-readout.
|
28917774 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
FUND: La Ligue contre le Cancer (équipe labelisée), INSERM, CEA, Université Paris-Diderot, Université Paris-Sud.
|
31130476 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Further serial studies are needed to determine whether changes in CEA titer can be indicators of polyp and/or cancer occurrence.
|
6851804 |
1983 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, T-bodies against CEA showed a startling ability to cause regression of malignant colon tumors in a nude mouse model of human cancer.
|
16507098 |
2006 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the CEA-specific CD8+ T-cell clones derived from cancer patients revealed low-functional avidity and impaired tumor-cell recognition.
|
17447064 |
2007 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In respect to the staining of (sialyl Lex) at focal dedifferentiation, it was positive in 17 of 24 cases (71%) in Group A, in 4 of 24 cases (17%) in Group B and in 11 of 20 cases (55%) in Group C. Focal dedifferentiation and sialyl Lex staining in the primary cancer showed a significant difference between Groups A and B. Sialyl Lex staining at focal dedifferentiation showed a significant difference between Groups A and B and Groups B and C. Other adhesion related molecules, sialyl LeA and CEA, showed no difference among Groups A, B, and C.
|
8826938 |
1996 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, most current prognostic tests in cancer (carcinoembryonary antigen [CEA], prostate-specific antigen [PSA], CA 19-1, CA 125, alpha-fetoprotein [AFP], etc.) are based on the detection and quantification of single proteins in body fluids.
|
12749728 |
2003 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Its overexpression in cancer cells is known to involve transcriptional activation of the CEA gene, but the underlying molecular details remain unclear.
|
17657737 |
2007 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, the CEACAM subfamily harbors the already established cancer biomarker CEA, as well as other potential molecular markers.
|
23525470 |
2013 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RESULTS KCS patients had higher plasma D-dimer, cancer antigen (CA) 125, and CEA levels and greater proteinuria levels than did KC patients.
|
28505148 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reverse transcription-polymerase chain reaction for CEA and SCC antigen mRNA was used to detect cancer cells in the peripheral blood.
|
20411433 |
2010 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Serum CEA levels in 49 different types of cancer and noncancer diseases.
|
30905451 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA.
|
11131674 |
2000 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The effects of utilizing graphene oxide, silica, and gold nanoparticles in cancer diagnosis were evaluated during the quantification of two major cancer biomarkers (CEA and AFP) in different approaches.
|
29149688 |
2018 |